Menu Search
Equities

Kyowa Kirin Co Ltd

KY4:FRA

Kyowa Kirin Co Ltd

Actions
  • Price (EUR)15.00
  • Today's Change0.00 / 0.00%
  • Shares traded114.00
  • 1 Year change+1.35%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 08:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kyowa Kirin Co Ltd, formerly Kyowa Hakko Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of prescription pharmaceuticals. The Company operates in a single pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has POTELLIGENT technology for producing active antibodies. The Company provides products include Poteligeo for the treatment of mycosis fungoides and sezary syndrome, and Crysvita for the treatment of X chromosome-linked hypophosphatemia. Besides, the Company also develops, manufactures, and markets biosimilar drugs, and engages in contracting, wholesale and retail business, and insurance agency business. The Company operates in Japan and overseas.

  • Revenue in JPY (TTM)498.98bn
  • Net income in JPY83.53bn
  • Incorporated1949
  • Employees5.97k
  • Location
    Kyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttps://www.kyowakirin.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.